PT-141 nasal spray is a real chapter in this compound's history rather than a current form of it. Bremelanotide, developed under the code name PT-141, was first taken into human trials as an intranasal spray, and that program was halted in 2007 after regulators raised concerns about dose-related blood-pressure increases. Development moved to subcutaneous injection. That is the route the phase 3 trials used, the route the approved product uses, and the route a compounded formulation uses. No intranasal bremelanotide product ever reached the market, so a nasal spray offered online today is not a discontinued medicine that resurfaced. It is something a seller assembled.
Why PT-141 was developed as a spray first
The reasoning was ordinary pharmacology. Bremelanotide is a cyclic seven-amino-acid peptide; swallowed, it would be degraded before reaching circulation, so a tablet was never realistic. The nasal mucosa is thin, richly supplied with blood, and sits close to the bloodstream, which makes it one of the few routes that can move a small peptide quickly without a needle. For an on-demand product taken shortly before sexual activity, speed and the absence of an injection both mattered.
The early data looked workable. In a double-blind, placebo-controlled study of intranasal PT-141 in healthy men and men with mild-to-moderate erectile dysfunction, exposure rose with dose, median time to peak concentration was half an hour, and half-life ran between roughly 1.85 and 2.09 hours (Diamond et al., Int J Impot Res 2004). Erectile response separated from placebo at doses above 7 mg, with onset around 30 minutes. Flushing and nausea were the most common adverse events, and no clinically significant vital-sign changes were observed in those early studies.
That last clause is the part worth holding onto. Small phase 1 and phase 2 studies are not usually where a dose-related cardiovascular signal shows itself.
Why the intranasal program was stopped
Melanocortin receptors are not confined to the brain circuits involved in sexual desire. Agonism at the melanocortin-4 receptor can raise blood pressure, and that is a class property rather than a quirk of one formulation. As the intranasal studies grew larger, blood pressure became the limiting issue, and in 2007 the planned phase 3 program in erectile dysfunction was delayed rather than started.
The regulatory record is visible in what came next. When the molecule was taken back into a phase 2b trial by subcutaneous injection, investigators built in two hours of manual blood-pressure measurement plus 24-hour ambulatory monitoring at every in-clinic dose, and stated plainly that the intensive monitoring was there to address concerns the FDA had raised after the earlier studies of the intranasal formulation (Clayton et al., Womens Health (Lond) 2016). Participants were withdrawn if sustained elevations crossed predefined thresholds.
Route was part of the problem, not only dose. Absorption across the nasal mucosa varies with congestion, with technique, with how much spray runs back down the throat, and between people. For most drugs that variability is a nuisance. For a compound whose principal safety signal tracks peak concentration, a route that produces unpredictable peaks is a poor match.
What changed when PT-141 moved to injection
The most visible change was the size of the dose. Intranasally, erectile response separated from placebo only above 7 mg. Subcutaneously it separated above 1.0 mg in healthy men, and men with erectile dysfunction were studied at 4 and 6 mg (Rosen et al., Int J Impot Res 2004). An injection places a known quantity into tissue and absorbs from there, in a way that does not depend on how a person's sinuses happen to be behaving.
Lower and more predictable exposure made the blood-pressure question measurable rather than alarming. In a randomised, placebo-controlled ambulatory monitoring trial in 397 premenopausal women, subcutaneous bremelanotide raised ambulatory systolic pressure by roughly 2.4 to 3.2 mmHg over placebo at 1.25 mg and 1.75 mg, with peak increases typically lasting under 15 minutes and heart rate falling about 4.6 to 4.7 beats per minute at the higher dose (White et al., J Hypertens 2017). Small, transient, and characterised.
What the approved injection actually is
The phase 3 RECONNECT trials settled on 1.75 mg subcutaneously as needed, across 1,267 randomised premenopausal women with hypoactive sexual desire disorder (Kingsberg et al., Obstet Gynecol 2019). A compounded preparation is not that product: Vyleesi, the FDA-approved bremelanotide injection that came out of those trials, carries a narrow label. It covers acquired, generalized HSDD in premenopausal women, at 1.75 mg by autoinjector into the abdomen or thigh at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than eight doses a month. It is not indicated in postmenopausal women or in men, and not indicated to enhance sexual performance.
The blood-pressure history is written into that label. It describes maximal transient increases of 6 mmHg systolic and 3 mmHg diastolic peaking two to four hours after a dose, a heart-rate reduction of up to 5 beats per minute, and a return to baseline usually within 12 hours — and it rules the drug out entirely in uncontrolled hypertension or known cardiovascular disease.
| Route | Where it stands | Doses studied |
|---|---|---|
| Intranasal spray | Development halted 2007; never marketed | Above 7 mg for a measurable erectile response |
| Subcutaneous injection, brand | Approved 2019 for acquired, generalized HSDD in premenopausal women | 1.75 mg as needed |
| Subcutaneous injection, compounded | Prepared by a licensed pharmacy on a prescription | Set by the reviewing provider |
What a PT-141 nasal spray sold online actually is
Because no intranasal bremelanotide product was ever marketed, a spray offered on a website is not a repurposed pharmaceutical. It is bulk peptide powder put into a nasal device by whoever is selling it, with no route-specific stability testing, no established nasal bioavailability figure for that particular preparation, and no clinician attached to the decision.
The dosing problem this creates is not the obvious one. The question is not only how many milligrams sit in the bottle, but how many of them cross the mucosa and reach circulation — which is precisely the variable the original program could not control well enough to keep the route. A number on a label is not a delivered dose. Our page on how PT-141 works covers the mechanism, and PT-141 dosage covers how the injectable amounts were arrived at.
There is a second problem specific to this compound. Its known effects include the transient blood-pressure rise described above, so cardiovascular history is a screening question rather than a footnote. Someone buying a spray with no medical review has not been asked about it.
What a prescriber weighs before writing for it
Through Promise, PT-141 is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation where they judge it appropriate — that decision is between you and your doctor.
What the reviewing provider reads for is fairly specific. Blood pressure, and whether it is controlled. Known cardiovascular disease. Current antihypertensives and anything else that changes how blood pressure or heart rate behaves. Nausea history, since nausea was the most common adverse event across the development program and the most common reason people stopped in the phase 3 studies (Clayton et al., J Womens Health 2022). And whether the complaint being described is one this compound is a coherent answer to at all.
Route is part of that judgment. A prescriber writing for PT-141 is writing for the form the safety data actually describes, which is the injection; the mood and libido hub covers where it sits beside the rest of that category. A licensed provider reviews every request and prescribes only when it is appropriate, and not everyone qualifies.